State of art and limitations in genetic engineering to induce stable chondrogenic phenotype

Abstract : Current protocols for chondrocyte expansion and chondrogenic differentiation of stem cells fail to reduce phenotypic loss and to mitigate hypertrophic tendency. To this end, cell genetic manipulation is gaining pace as a means of generating cells with stable chondrocyte phenotype. Herein, we provide an overview of candidate genes that either induce cartilage regeneration or inhibit cartilage degeneration. We further discuss in vitro, ex vivo and in vivo viral transduction and non-viral transfection strategies for targeted cells (chondrocytes, me-senchymal stem cells, induced pluripotent stem cells and synovial cells), along with the most representative results obtained in pre-clinical models and in clinical trials. We highlight current challenges and associated risks that slowdown clinical acceptance and commercialisation of gene transfer technologies.
Complete list of metadatas

https://www.hal.inserm.fr/inserm-01848216
Contributor : Valérie Pecqueret <>
Submitted on : Tuesday, July 24, 2018 - 2:13:56 PM
Last modification on : Friday, April 5, 2019 - 1:16:35 AM
Long-term archiving on : Thursday, October 25, 2018 - 3:34:59 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

Valeria Graceffa, Claire Vinatier, Jérôme Guicheux, Christopher Evans, Martin Stoddart, et al.. State of art and limitations in genetic engineering to induce stable chondrogenic phenotype. Biotechnology Advances, Elsevier, 2018, ⟨10.1016/j.biotechadv.2018.07.004⟩. ⟨inserm-01848216⟩

Share

Metrics

Record views

628